Member Info for Knotagain

Can't wait for another explosive week.

Don't forget the biscuits.

If you held off for a couple of weeks you'd probably be able to sell for around 150.

You plonker.

They can order what they like, they won't be getting my shares.

That would be nice 🙂

Well done Avacta 👏

Keep up the good work.

There's one thing for sure, Alastair Smith isn't stupid.

Avacta have acquired Coris Bioconcept for a very good reason, onwards Avacta.

If we all filtered wyndrum we wouldn't have to talk about him most of the time.

Enough said.

Make that 23 posts.

Lanbt, 21 posts on Avacta - all negative.

Cheer up mate.

Once again I could only buy in small batches, read into that what you will.

Best of luck 👍

Minced fillet steak in my Bolognese on my yacht.

Calm before the storm?

129, best of luck.

Took me ages to top up £10,000 this morning, had to do it in blocks of 1,000.
Can only think that a large order was being filled.

Avacta (LON: AVCT)

Avacta is currently proceeding with clinical trials of its flagship AVA6000 — which it hopes will deliver ‘chemotherapy without the side effects.’

The company recently announced that the first patient of the fifth cohort of the flagship AVA6000 Phase 1a Dose Escalation Study has been dosed with the treatment in the UK — this first in-human phase I trial includes MHRA approval for higher dosages — at a level of 250mg/m2. The idea is to find out the maximum tolerable dose for further clinical trials.

CEO Alastair Smith notes that ‘the recent confirmation of release of active chemotherapy in the tumour tissue and the safety data being generated in the ALS-6000-101 study are providing detailed insights.’

The company has also opened two US Clinical Investigator Sites for AVA6000 Phase 1, one at the Memorial Sloan Kettering Cancer Center and the second at the Fred Hutch Cancer Center. Enrolment for soft tissue sarcoma patients has begun, with trials led by globally renowned oncologists Dr William Tap and Dr Lee Cramer.

Avacta has hinted that phase 1B may be conducted initially across the pond, claiming that stateside is ‘uniquely positioned’ for further research. CDO Neil Bell has highlighted the recent ‘major milestone,’ and plans to ‘build the clinical evidence base for the safety and tolerability of AVA6000.’

Further clinical success could see the share price rocket — and a buyout or US listing — could come at any time.

We need all the helpful press coverage we can get.

Agent, sorry to hear that you have had to return to work recently, that must be awful.

https://www.fool.co.uk/2023/03/15/is-the-avacta-share-price-dip-a-buying-opportunity/

Absolutely clueless.

I've gone and bought the Multi- User package at $750 because it's the most popular.

What a load of sewage.